Trials / Completed
CompletedNCT00093119
Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
A Phase II Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-007 |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2005-02-01
- First posted
- 2004-10-04
- Last updated
- 2017-04-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00093119. Inclusion in this directory is not an endorsement.